Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $1,132 | 13 | 88.1% |
| Food and Beverage | $153.01 | 5 | 11.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $691.85 | 9 | $0 (2019) |
| Incyte Corporation | $154.95 | 2 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $133.53 | 3 | $0 (2018) |
| Pharmacyclics LLC, An AbbVie Company | $99.00 | 1 | $0 (2019) |
| Seattle Genetics, Inc. | $99.00 | 1 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $90.50 | 1 | $0 (2019) |
| Janssen Biotech, Inc. | $16.58 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $16.58 | 1 | Janssen Biotech, Inc. ($16.58) |
| 2019 | $701.38 | 9 | Astellas Pharma US Inc ($357.88) |
| 2018 | $432.47 | 6 | Astellas Pharma US Inc ($198.99) |
| 2017 | $134.98 | 2 | Astellas Pharma US Inc ($134.98) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/04/2022 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: Oncology | ||||||
| 12/20/2019 | Seattle Genetics, Inc. | — | Education | In-kind items and services | $99.00 | General |
| 12/13/2019 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.99 | General |
| 11/21/2019 | Takeda Pharmaceuticals U.S.A., Inc. | VELCADE (Drug) | Education | In-kind items and services | $90.50 | General |
| Category: Oncology | ||||||
| 11/05/2019 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Education | In-kind items and services | $99.00 | General |
| Category: Oncology | ||||||
| 10/31/2019 | Astellas Pharma US Inc | — | Education | In-kind items and services | $95.00 | General |
| 09/13/2019 | Incyte Corporation | — | Education | Cash or cash equivalent | $55.00 | General |
| 08/27/2019 | Astellas Pharma US Inc | — | Education | In-kind items and services | $95.00 | General |
| 08/27/2019 | Astellas Pharma US Inc | — | Education | In-kind items and services | $64.99 | General |
| 08/27/2019 | Astellas Pharma US Inc | CRESEMBA (Drug), MYCAMINE, AMBISOME | Food and Beverage | In-kind items and services | $2.90 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 12/06/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 10/15/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.99 | General |
| 07/03/2018 | Incyte Corporation | — | Education | Cash or cash equivalent | $99.95 | General |
| 06/04/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $36.70 | General |
| Category: ONCOLOGY | ||||||
| 06/04/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $31.27 | General |
| Category: ONCOLOGY | ||||||
| 05/30/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $65.56 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $74.99 | General |
| 12/05/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $59.99 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 145 | 329 | $75,318 | $15,998 |
| 2022 | 5 | 88 | 208 | $29,748 | $6,479 |
| 2021 | 6 | 124 | 224 | $42,459 | $10,938 |
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 46 | 95 | $47,310 | $9,903 | 20.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 19 | 27 | $9,045 | $1,799 | 19.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $7,188 | $1,472 | 20.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $5,038 | $905.67 | 18.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 28 | 98 | $2,058 | $823.20 | 40.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 13 | 26 | $2,834 | $631.45 | 22.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 17 | 61 | $1,845 | $464.21 | 25.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 20 | 38 | $17,708 | $3,964 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 20 | 27 | $8,559 | $1,856 | 21.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 16 | 53 | $1,603 | $375.86 | 23.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 21 | 78 | $1,638 | $222.21 | 13.6% |
| 82565 | Blood creatinine level | Office | 2022 | 11 | 12 | $240.00 | $60.84 | 25.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 37 | 58 | $14,616 | $3,876 | 26.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 18 | 30 | $10,680 | $3,031 | 28.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 14 | 14 | $9,030 | $2,181 | 24.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 11 | 17 | $5,644 | $1,367 | 24.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 20 | 42 | $1,229 | $303.36 | 24.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 24 | 63 | $1,260 | $180.00 | 14.3% |
About Dr. Christine Ding, M.D
Dr. Christine Ding, M.D is a Hematology & Oncology healthcare provider based in Saint Paul, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/08/2014. The National Provider Identifier (NPI) number assigned to this provider is 1487073300.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christine Ding, M.D has received a total of $1,285 in payments from pharmaceutical and medical device companies, with $16.58 received in 2022. These payments were reported across 18 transactions from 7 companies. The most common payment nature is "Education" ($1,132).
As a Medicare-enrolled provider, Ding has provided services to 357 Medicare beneficiaries, totaling 761 services with total Medicare billing of $33,416. Data is available for 3 years (2021–2023), covering 18 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Saint Paul, MN
- Active Since 04/08/2014
- Last Updated 03/16/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1487073300
Products in Payments
- KEYTRUDA (Biological) $133.53
- Imbruvica (Drug) $99.00
- VELCADE (Drug) $90.50
- ERLEADA (Drug) $16.58
- CRESEMBA (Drug) $2.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Saint Paul
Yan Ji, M.d, Ph.d, M.D, PH.D
Hematology & Oncology — Payments: $71,539
Kurt Demel, Md, MD
Hematology & Oncology — Payments: $22,510
Daniel Anderson, Md, MD
Hematology & Oncology — Payments: $13,524
Dr. Sara Torgerson, D.o, D.O
Hematology & Oncology — Payments: $988.23
Timothy Toonen, M.d, M.D
Hematology & Oncology — Payments: $595.24
Dr. Bhaskar Kolla, M.d, M.D
Hematology & Oncology — Payments: $125.00